Indications › Type 2 diabetes › exenatide

exenatide in type 2 diabetes

exenatide is approved in the US for type 2 diabetes, and has 121 trials on file here in this condition. 105 of them are phase 3 or later. No trial here has a completion date still in the future, so this is a closed body of work rather than an active programme.

121 registered trials study exenatide (Bydureon, Byetta) in type 2 diabetes, 1 of them still active and 1 in phase 3. None has a scheduled reporting date on file.

Trials on file: 121
Active: 1
Active phase 3: 1
Participants in active trials: 270
Sponsors: 49
Scheduled readouts: 0

All trials on file

Every registered trial of exenatide grouped under type 2 diabetes, largest first. Grouping follows the registry’s own condition wording.

Trial	Status	Phase	Sponsor
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus NCT01144338	Completed	P3	AstraZeneca
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650 NCT01455896	Completed	P3	Intarcia Therapeutics
A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both. NCT00717457	Completed	P3	Hoffmann-La Roche
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes NCT00960661	Completed	P3	AstraZeneca
Exenatide Versus Glimepiride in Patients With Type 2 Diabetes NCT00359762	Completed	P3	AstraZeneca
Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) NCT00676338	Completed	P3	AstraZeneca
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus NCT00035984	Completed	P3	AstraZeneca
A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects NCT00917267	Completed	P3	AstraZeneca
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin NCT00707031	Completed	P3	Sanofi
Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy NCT04504396	Completed	P3	PegBio Co., Ltd.
Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin NCT00082381	Completed	P3	AstraZeneca
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes NCT01455870	Completed	P3	Intarcia Therapeutics
A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2) NCT00637273	Completed	P3	AstraZeneca
Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin NCT00082407	Completed	P3	AstraZeneca
Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes NCT00434954	Completed	P3	AstraZeneca
Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3) NCT00641056	Completed	P3	AstraZeneca
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin NCT00324363	Completed	P3	AstraZeneca
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes NCT01455857	Completed	P3	Intarcia Therapeutics
Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes NCT00111540	Completed	P3	AstraZeneca
The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus NCT03239119	Unknown	P3	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus NCT00935532	Completed	P3	AstraZeneca
A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes NCT02119819	Completed	P2	OPKO Health, Inc.
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea NCT00039026	Completed	P3	AstraZeneca
Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes NCT01652716	Completed	P3	AstraZeneca
Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes NCT00359879	Completed	P3	AstraZeneca
Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea. NCT00313001	Completed	P3	Novo Nordisk A/S
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus NCT01652729	Completed	P3	AstraZeneca
Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only NCT00518115	Completed	P2	GlaxoSmithKline
Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM NCT02467920	Completed	P4	Huazhong University of Science and Technology
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide NCT00560417	Completed	P3	Eli Lilly and Company
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin NCT00039013	Completed	P3	AstraZeneca
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) NCT00308139	Completed	P3	AstraZeneca
An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus NCT01876849	Completed	P3	AstraZeneca
Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects NCT04504370	Completed	P3	PegBio Co., Ltd.
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients NCT06254014	Active, not recruiting	P3	Beijing Dongfang Biotech Co., Ltd.
Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus NCT00765817	Completed	P3	AstraZeneca
A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin NCT00870194	Completed	P4	AstraZeneca
A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5) NCT00877890	Completed	P3	AstraZeneca
Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin NCT03060980	Terminated	P3	Intarcia Therapeutics
Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes. NCT02288273	Completed	P4	AstraZeneca
A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients NCT00360334	Completed	P3	AstraZeneca
Safety and Efficacy of Exenatide as Monotherapy NCT00381342	Completed	P3	AstraZeneca
Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes NCT03297879	Completed	P4	Beijing Chao Yang Hospital
Extension Study for 2993-112 NCT01789957	Completed	P3	AstraZeneca
Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes NCT01003184	Completed	P3	AstraZeneca
Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes NCT02081118	Completed	P2	Hanmi Pharmaceutical Company Limited
A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese NCT03018665	Unknown	P4	The First Hospital of Jilin University
Effect on Weight Loss of Exenatide Versus Placebo NCT00375492	Completed	P3	AstraZeneca
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin NCT00099320	Completed	P3	AstraZeneca
Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) NCT00577824	Completed	P3	AstraZeneca
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin NCT00603239	Completed	P3	AstraZeneca
The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients NCT01270191	Unknown	P4	Taipei Veterans General Hospital, Taiwan
Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus NCT00044694	Completed	P2	AstraZeneca
Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients NCT01776788	Completed	P4	The First Affiliated Hospital of Xiamen University
Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination NCT00044668	Completed	P3	AstraZeneca
Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus NCT00943917	Completed	P2	Intarcia Therapeutics
A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes NCT00382239	Completed	P2	AstraZeneca
Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes NCT02449603	Completed	P4	Xijing Hospital
Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes NCT02455076	Completed	P4	Emory University
Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus NCT02162550	Unknown	P4	Phoenix VA Health Care System

See the full record for exenatide, or every molecule being studied in type 2 diabetes. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.